Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › temozolomide

temozolomide

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of temozolomide

143 trials tracked of temozolomide: 13 in phase 3 or 4 and 6 with published results. The most-cited published study has 2833 citations.

143Trials tracked
13Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 2 Phase 3 11 Phase 2 112 Phase 1 13 Other / NA 5
  1. Phase 3 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed · 2,833 cited
  2. Phase 3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed · 1,194 cited
  3. Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 530 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 516 cited
  5. Phase 3 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Completed · 112 cited
  6. Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Completed · 27 cited
Show 44 more trials
  1. Phase 4 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed
  2. Phase 4 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed
  3. Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed
  4. Phase 3 A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma Completed
  5. Phase 3 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed
  6. Phase 3 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed
  7. Phase 3 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed
  8. Phase 2 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
  9. Phase 2 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed
  10. Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide Completed
  11. Phase 2 Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. Completed
  12. Phase 2 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Completed
  13. Phase 2 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme Completed
  14. Phase 2 Temozolomide Chronotherapy for High Grade Glioma Completed
  15. Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed
  16. Phase 2 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme Completed
  17. Phase 2 A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed
  18. Phase 2 Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases Completed
  19. Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Completed
  20. Phase 2 Temozolomide in Treating Patients With Low-Grade Glioma Completed
  21. Phase 2 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Completed
  22. Phase 2 ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer Completed
  23. Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma Completed
  24. Phase 2 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed
  25. Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
  26. Phase 2 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed
  27. Phase 2 Dose-Intense Temozolomide in Recurrent Glioblastoma Completed
  28. Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed
  29. Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma Completed
  30. Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Completed
  31. Phase 2 Bevacizumab Beyond Progression (BBP) Completed
  32. Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Completed
  33. Phase 2 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Completed
  34. Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed
  35. Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
  36. Phase 2 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases Completed
  37. Phase 2 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma Completed
  38. Phase 2 Study of MLN8237 in Combination With Irinotecan and Temozolomide Completed
  39. Phase 2 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed
  40. Phase 2 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Completed
  41. Phase 2 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer Completed
  42. Phase 2 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Completed
  43. Phase 2 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Completed
  44. Phase 2 A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer Completed

Showing the 50 most-cited and recently-updated of 143 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune checkpoint inhibitors failed to demonstrate durable benefit in three large glioblastoma phase III trials
Drug Pipeline Sys. Review
Immune checkpoint inhibitors failed to demonstrate durable benefit in three large glioblastoma phase III trials Immune Checkpoint Inhibitors Show Limited Success for Glioblastoma Patients
This narrative review examines the current landscape of immune checkpoint inhibitors in glioblastoma management. The review notes that three…
Recent reviews of large clinical trials show that immune checkpoint inhibitors have not yet provided lasting benefits for patients with glio…
Frontiers Sep 13, 2026
Glioblastoma with transdural extension and skull base involvement presents as a rare clinical scenario
Orthopedics & Sports Medicine Sys. Review
Glioblastoma with transdural extension and skull base involvement presents as a rare clinical scenario Case Report Shows Treatment Success for Rare Glioblastoma Presentation
This case report and literature review describes a single 63-year-old male with glioblastoma involving the skull base. The patient remained …
A new case report highlights how specific surgical and medical treatments helped manage a rare type of brain tumor involving the skull base.
Frontiers Aug 7, 2026
Spatial patterns of glioblastoma progression following upfront chemoradiation and salvage therapy
Oncology Meta-analysis
Spatial patterns of glioblastoma progression following upfront chemoradiation and salvage therapy Analysis shows where glioblastoma tumors typically grow after treatment
Researchers analyzed the spatial patterns of tumor progression in patients with glioblastoma after standard chemoradiation and subsequent sa…
New data reveals that most glioblastoma tumors grow near the original site, helping doctors better understand how the cancer spreads after r…
Jul 31, 2026
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Oncology Meta-analysis
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
May 1, 2026
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review
Oncology
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review Why tumors grow back inside the radiation beam, not just at the edges
This retrospective single-center review of 41 patients with high-grade glioma found that central recurrence was the most common pattern (36.…
New data shows brain tumors often return in the middle of the radiation zone, suggesting biology, not just targeting errors, drives failure.
medRxiv Apr 26, 2026
Narrative review on ferroptosis-targeting strategies for glioblastoma modulation
Diabetes & Endocrinology Sys. Review
Narrative review on ferroptosis-targeting strategies for glioblastoma modulation New Brain Tumor Strategy Targets Iron to Boost Immune Attack
This narrative review synthesizes mechanisms and strategies for targeting ferroptosis in glioblastoma.
This new approach uses the tumor's own iron problem to help the body's immune system destroy cancer cells more effectively.
Frontiers Apr 16, 2026
Bibliometric analysis maps 4.3-fold rise in elderly glioma research, highlights MGMT focus
Oncology RCT
Bibliometric analysis maps 4.3-fold rise in elderly glioma research, highlights MGMT focus Why is brain tumor research for older adults lagging behind? A new analysis reveals a critical gap
A bibliometric analysis of 1,299 publications found a 4.3-fold increase in research on elderly glioma from 2001 to 2025, with the U.S., Ital…
Glioma research for older adults lags behind because studies focus on younger patients, leaving a critical gap in treating aggressive tumors…
Frontiers Mar 30, 2026